Targeting homologous recombination-mediated DNA repair in cancer (Q38184667)

30 August 2017

Targeting homologous recombination-mediated DNA repair in cancer (English)

1 reference

30 August 2017

João F S Carvalho

1

1 reference

PubMed ID

24491188

30 August 2017

Roland Kanaar

series ordinal

2

1 reference

PubMed ID

24491188

30 August 2017

language of work or name

English

0 references

publication date

4 February 2014

1 reference

Expert Opinion on Therapeutic Targets

30 August 2017

1 reference

30 August 2017

18

1 reference

30 August 2017

427-458

1 reference

30 August 2017

4

1 reference

Combinatorial drug therapy for cancer in the post-genomic era.

30 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

DNA repair pathways as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

DNA repair dysregulation from cancer driver to therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Quantitative live cell imaging reveals a gradual shift between DNA repair mechanisms and a maximal use of HR in mid S phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Role of ABL family kinases in cancer: from leukaemia to solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Imatinib radiosensitizes bladder cancer by targeting homologous recombination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Targeting ATR in DNA damage response and cancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Anticancer therapy with checkpoint inhibitors: what, where and when?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

BLM-DNA2-RPA-MRN and EXO1-BLM-RPA-MRN constitute two DNA end resection machineries for human DNA break repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

ATP-dependent and independent functions of Rad54 in genome maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

BRCA2-dependent and independent formation of RAD51 nuclear foci.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Functions of the Snf2/Swi2 family Rad54 motor protein in homologous recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

In situ visualization of DNA double-strand break repair in human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

The MRE11 complex: starting from the ends.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Ataxia telangiectasia-mutated (ATM) kinase activity is regulated by ATP-driven conformational changes in the Mre11/Rad50/Nbs1 (MRN) complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Making the best of the loose ends: Mre11/Rad50 complexes and Sae2 promote DNA double-strand break resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Molecular disruption of the MRN(95) complex induces radiation sensitivity in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Molecular disruption of NBS1 with targeted gene delivery enhances chemosensitisation in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Mutant Nbs1 enhances cisplatin-induced DNA damage and cytotoxicity in head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Disruption of telomere maintenance by depletion of the MRE11/RAD50/NBS1 complex in cells that use alternative lengthening of telomeres

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Role of MRE11 in cell proliferation, tumor invasion, and DNA repair in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Telomerase-specific replication-selective virotherapy for human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Inhibition of hsp90 compromises the DNA damage response to radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Corrected structure of mirin, a small-molecule inhibitor of the Mre11-Rad50-Nbs1 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Mre11-Rad50 complex crystals suggest molecular calisthenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Replication protein A is an independent prognostic indicator with potential therapeutic implications in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

A relationship between replication protein A and occurrence and prognosis of esophageal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Prognostic significance of replication protein A (RPA) expression levels in bladder urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Replication protein A: a reliable biologic marker of prognostic and therapeutic value in human astrocytic tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

DNA replication defects, spontaneous DNA damage, and ATM-dependent checkpoint activation in replication protein A-deficient cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Functions of human replication protein A (RPA): from DNA replication to DNA damage and stress responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

A dynamic model for replication protein A (RPA) function in DNA processing pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Role of interaction of XPF with RPA in nucleotide excision repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Physical interaction between replication protein A and Rad51 promotes exchange on single-stranded DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

RPA facilitates rejoining of DNA double-strand breaks in an in vitro assay utilizing genomic DNA as substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Viral interference with DNA repair by targeting of the single-stranded DNA binding protein RPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Inhibition of cell survival and invasive potential of colorectal carcinoma cells by the tyrosine kinase inhibitor STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

A high-throughput fluorescence polarization anisotropy assay for the 70N domain of replication protein A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Targeted inhibition of Replication Protein A reveals cytotoxic activity, synergy with chemotherapeutic DNA-damaging agents, and insight into cellular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Novel irreversible small molecule inhibitors of replication protein A display single-agent activity and synergize with cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Physical interaction between replication protein A (RPA) and MRN: involvement of RPA2 phosphorylation and the N-terminus of RPA1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Interaction between BRCA2 and replication protein A is compromised by a cancer-predisposing mutation in BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Analysis of the human replication protein A:Rad52 complex: evidence for crosstalk between RPA32, RPA70, Rad52 and DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Physical and functional mapping of the replication protein a interaction domain of the werner and bloom syndrome helicases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Small molecule inhibitor of the RPA70 N-terminal protein interaction domain discovered using in silico and in vitro methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Discovery of Protein–Protein Interaction Inhibitors of Replication Protein A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

BRCA1 and BRCA2: different roles in a common pathway of genome protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

The epistatic relationship between BRCA2 and the other RAD51 mediators in homologous recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Secondary mutations of BRCA1/2 and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

PARP inhibitors in cancer therapy: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Hereditary breast cancer: new genetic developments, new therapeutic avenues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Down regulation of BRCA2 causes radio-sensitization of human tumor cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined "Complementary Lethality".

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Involvement of Brca2 in DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Structure-activity relationship studies to probe the phosphoprotein binding site on the carboxy terminal domains of the breast cancer susceptibility gene 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Exploiting the P-1 pocket of BRCT domains toward a structure guided inhibitor design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Dual-fluorophore quantitative high-throughput screen for inhibitors of BRCT-phosphoprotein interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

MicroRNAs and DNA damage response: implications for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Developing therapeutic microRNAs for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Small-molecule inhibitors of the PI3K signaling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

PARP inhibitors--current status and the walk towards early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Attenuated DNA damage repair by trichostatin A through BRCA1 suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Adamantanyl-histone deacetylase inhibitor H6CAHA exhibits favorable pharmacokinetics and augments prostate cancer radiation sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Targeting the dynamic HSP90 complex in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Inhibition of Hsp90: a multitarget approach to radiosensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

The vital link between the ubiquitin-proteasome pathway and DNA repair: impact on cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Targeted disruption of the Rad51 gene leads to lethality in embryonic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Overexpression of RAD51 occurs in aggressive prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Elevated expression of Rad51 is correlated with decreased survival in resectable esophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Rad51 protein expression and survival in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Impaired homologous recombination DNA repair and enhanced sensitivity to DNA damage in prostate cancer cells exposed to anchorage-independence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

The consequences of Rad51 overexpression for normal and tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient's outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

RAD51 mutants cause replication defects and chromosomal instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Antisense inhibition of the RAD51 enhances radiosensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Targeting of Rad51-dependent homologous recombination: implications for the radiation sensitivity of human lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

HSV-1 amplicon-mediated post-transcriptional inhibition of Rad51 sensitizes human glioma cells to ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Knockdown of Rad51 expression induces radiation- and chemo-sensitivity in osteosarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Defective homologous recombination in human cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Use of the Rad51 promoter for targeted anti-cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Adenoviral vector driven by a minimal Rad51 promoter is selective for p53-deficient tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Methotrexate-mediated inhibition of RAD51 expression and homologous recombination in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Modulation of radiation response by histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Berberine radiosensitizes human esophageal cancer cells by downregulating homologous recombination repair protein RAD51

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Insights into DNA recombination from the structure of a RAD51-BRCA2 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Expression of BRC repeats in breast cancer cells disrupts the BRCA2-Rad51 complex and leads to radiation hypersensitivity and loss of G(2)/M checkpoint control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Design of potent inhibitors of human RAD51 recombinase based on BRC motifs of BRCA2 protein: modeling and experimental validation of a chimera peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Targeting human Rad51 by specific DNA aptamers induces inhibition of homologous recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Inhibition of the ATR/Chk1 pathway induces a p38-dependent S-phase delay in mouse embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Caffeine inhibits checkpoint responses without inhibiting the ataxia-telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Homologous recombination as a potential target for caffeine radiosensitization in mammalian cells: reduced caffeine radiosensitization in XRCC2 and XRCC3 mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Caffeine inhibits homology-directed repair of I-SceI-induced DNA double-strand breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Eme1 is involved in DNA damage processing and maintenance of genomic stability in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Caffeine suppresses homologous recombination through interference with RAD51-mediated joint molecule formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

DIDS, a chemical compound that inhibits RAD51-mediated homologous pairing and strand exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Attenuating homologous recombination stimulates an AID-induced antileukemic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

DIDS (4,4-diisothiocyanatostilbenedisulphonic acid) induces apoptotic cell death in a hippocampal neuronal cell line and is not neuroprotective against ischemic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Halenaquinone, a chemical compound that specifically inhibits the secondary DNA binding of RAD51.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Halenaquinone and xestoquinone derivatives, inhibitors of Cdc25B phosphatase from a Xestospongia sp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Halenaquinone, a novel phosphatidylinositol 3-kinase inhibitor from a marine sponge, induces apoptosis in PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Inhibition of homologous recombination in human cells by targeting RAD51 recombinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Mediator function of the human Rad51B-Rad51C complex in Rad51/RPA-catalyzed DNA strand exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Xrcc3 is required for assembly of Rad51 complexes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Mammalian Rad51C contributes to DNA cross-link resistance, sister chromatid cohesion and genomic stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

A hot spot for RAD51C interactions revealed by a peptide that sensitizes cells to cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Targeted inactivation of mouse RAD52 reduces homologous recombination but not resistance to ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Homologous recombination, but not DNA repair, is reduced in vertebrate cells deficient in RAD52.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Stimulation by Rad52 of yeast Rad51-mediated recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Unraveling the mechanism of BRCA2 in homologous recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Rad52 inactivation is synthetically lethal with BRCA2 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

PALB2 links BRCA1 and BRCA2 in the DNA-damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

DNA helicases involved in DNA repair and their roles in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

The RecQ DNA helicases in DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Human RECQ1 interacts with Ku70/80 and modulates DNA end-joining of double-strand breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Human RECQ1 is a DNA damage responsive protein required for genotoxic stress resistance and suppression of sister chromatid exchanges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

The human RECQ1 helicase is highly expressed in glioblastoma and plays an important role in tumor cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

RECQL1 and WRN proteins are potential therapeutic targets in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

RECQ1 is required for cellular resistance to replication stress and catalyzes strand exchange on stalled replication fork structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

The human WRN and BLM RecQ helicases differentially regulate cell proliferation and survival after chemotherapeutic DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Potential role for the BLM helicase in recombinational repair via a conserved interaction with RAD51

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Mobile D-loops are a preferred substrate for the Bloom's syndrome helicase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

The Bloom's syndrome helicase suppresses crossing over during homologous recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

A small molecule inhibitor of the BLM helicase modulates chromosome stability in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Synthesis and SAR studies of 5-(pyridin-4-yl)-1,3,4-thiadiazol-2-amine derivatives as potent inhibitors of Bloom helicase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Hitting the bull's eye: novel directed cancer therapy through helicase-targeted synthetic lethality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

DNA double-strand break repair: all's well that ends well

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Targeting the fanconi anemia pathway to identify tailored anticancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Ouabain, a cardiac glycoside, inhibits the Fanconi anemia/BRCA pathway activated by DNA interstrand cross-linking agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Disruption of mouse RAD54 reduces ionizing radiation resistance and homologous recombination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Homologous and non-homologous recombination differentially affect DNA damage repair in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Differential contributions of mammalian Rad54 paralogs to recombination, DNA damage repair, and meiosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

Fluorescent Human RAD51 Reveals Multiple Nucleation Sites and Filament Segments Tightly Associated along a Single DNA Molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.882900

10.1517/14728222.2014.882900

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24491188